Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for cancer, viral diseases, and immune disorders. This dedicated news hub provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access verified information about Ampligen clinical progress, Alferon N Injection research, and collaborative studies with global institutions. Our curated news collection covers FDA communications, trial phase results, intellectual property updates, and scientific conference presentations.
Key updates include oncology treatment advancements, antiviral therapy research, and partnership announcements with organizations like Japan's National Institute of Infectious Diseases. Bookmark this page for real-time access to AIM's latest developments in immuno-pharmaceutical innovation.
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive data analysis from a study on Ampligen in treating advanced pancreatic cancer. The study shows immune-stimulatory properties of TLR-3 activation, enhancing anti-tumor immunity through dendritic cell-mediated T cell responses. Ampligen treatment correlates with improved clinical outcomes and decreased expression of immune checkpoints. The company aims to expand Ampligen's application to various solid tumor types, with ongoing clinical trials to evaluate its effectiveness in pancreatic cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces the publication of the CEO Corner segment featuring Thomas Equels, discussing corporate overview, business outlook, and the AIM opportunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. releases CEO Corner segment discussing Advanced Recurrent Ovarian Cancer and clinical development milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) will present at the Virtual Investor Lunch Break event with CEO Tom Equels on March 20th, discussing the company's business outlook and opportunities. The live video webcast will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. launches CEO Corner featuring Thomas K Equels to provide additional perspective on press releases, corporate developments, and pipeline progress. The platform aims to connect directly with stockholders, offering expanded insights on clinical trials and corporate advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. highlights progress in Ampligen clinical development programs for various indications, including Post-COVID conditions, pancreatic cancer, and ovarian cancer. Recent accomplishments include positive results in the AMP-518 study and the DURIPANC study. The company emphasizes building upon scientific success and anticipates significant value for stockholders. Upcoming milestones include interim results for advanced recurrent ovarian cancer and final dataset for Post-COVID conditions in Q1 and Q2 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. announced the dosing of the first subject in a Phase 1b/2 clinical trial combining Ampligen with Imfinzi for late-stage pancreatic cancer treatment. The study is expected to be completed within six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive topline results from Phase 2 study of Ampligen in treating Post-COVID fatigue. Initial analysis shows lower fatigue levels in Ampligen group at multiple time points. The Six-Minute Walk Test also reveals a higher impact of Ampligen on distance traveled compared to placebo. Safety results indicate Ampligen is generally well-tolerated with no severe adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.64%
Tags
-
Rhea-AI Summary
AIM ImmunoTech Inc. has received authorization from the Erasmus Medical Center Ethics Committee to open a European site for the ongoing Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer. The approval is a significant step towards enrolling subjects in the European arm of the clinical trial. The study aims to compare the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Subject enrollment is expected in Q1 2024, with approximately 90 subjects to be enrolled in the United States and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
Rhea-AI Summary
AIM ImmunoTech Inc. announced the enrollment of the first subject in a Phase 1b/2 clinical trial combining Ampligen with AstraZeneca’s Imfinzi for late-stage pancreatic cancer treatment. Positive clinical data could make AIM an attractive buyout target. AIM secured a U.S. patent for Ampligen's use in combination therapy. The trial aims to determine safety and clinical benefit rates of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Aim Immunotech
NYSE:AIM
AIM Rankings
AIM Stock Data
6.52M
67.24M
10.11%
12.54%
4.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
OCALA